Thrombophilia work-up and clinical outcomes in Indian patients with unprovoked venous and arterial thrombosis aged 18-50 years | BTVB Bioequivalence of von Willebrand factor-containing concentrates: implications for von Willebrand disease | BTVB Cardiovascular risk in hormone replacement therapy | BTVB Direct oral anticoagulants: does one dose fit all? Why, when and how testing | BTVB Cardiovascular risk profile evolution over 15 years: CV-PREVITAL vs Moli-sani Study | BTVB Launch of National Registry for Congenital Hematological Disorders in Palestine: Haemo-PAL | BTVB

This journal has not published any issues.

Impact Factor 2025

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

By Issue

Search Results

##search.searchResults.foundPlural##

PO25 | Baseline thrombin generation test does not predict thrombotic events in acute leukemia: a monocentric prospective study M. Biglietto, R. Mormile, M.L. Bisegna, A. Laganà, A. L. Faccini, A. Papa, E. Baldacci, C. Santoro, M.S. De Propris, A. Chistolini | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy

22-10-2025

https://doi.org/10.4081/btvb.2025.286

654

PDF: 13
CO063 | NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A POTENTIAL PREDICTOR OF THROMBOSIS IN CLASSICAL HODGKIN LYMPHOMA: AN EXPLORATORY ANALYSIS M. Biglietto¹, G.M. Assanto^1|2, S. Palladino¹, G. Annechini¹, G.M. D'Elia², M.S. De Propris^1|2, I. Del Giudice^1|2, A. Chistolini¹ | ¹Sapienza, University of Roma, Italy; ²AOU Policlinico Umberto I, Roma, Italy

Mario Biglietto

26-10-2026

https://doi.org/10.4081/btvb.2026.765

24

PDF: 9

1 - 2 of 2 items

© PAGEPress 2008-2026 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185
This journal is published by PAGEPress® srl (Pavia, Italy), which is the data controller for all personal data processed through this platform. For full details on how your data is collected, used and protected, please read our Privacy Policy.